The influence of proteasome inhibitor on the expression of cardiomyocytes damage markers after incubation with doxorubicin

Sylwia Tereszkiewicz; Wlodzimierz Matysiak; Slawomir Mandziuk; Agnieszka Korga; Malgorzata Oleksiejuk; Marcin Hejna; Agnieszka Korobowicz-Markiewicz; Magdalena Iwan; Jaroslaw Dudka

doi:10.2478/cipms-2014-0020

Abstract

The aim of the study was to verify the thesis that the cardiotoxic effects of doxorubicin are connected with activation of the ubiquitin - proteasome pathway followed by protein degradation. The expression of myocardial damage markers - fatty acid binding protein (H-FABP) and brain natriuretic peptide (BNP) was evaluated in rat fetal cardiomyocytes simultaneously treated with doxorubicin and the proteasome inhibitor - bortezomib. The level of H-FABP and BNP protein under the influence of doxorubicin was decreased below the detection threshold with unchanged (H-FABP) or elevated (BNP) mRNA expression level. Against the expectations, the inhibitor of proteasome did not abolish this effect. The observed abnormal expression of BNP and H-FABP protein after doxorubicin treatment makes their diagnostic significance in anthracycline cardiotoxicity questionable.

References

1. Adams J.: Development of the Proteasome Inhibitor PS-341. The Oncologist, 7, 9, 2002.10.1634/theoncologist.7-1-911854543
Search in Google Scholar
2. Aihara Y. et al.: Doxorubicin Represses CARP Gene Transcription Through the Generation of Oxidative Stress in Neonatal Rat Cardiac Myocytes: Possible Role of Serine/Threonine Kinase - dependent Pathways. J. Mol. Cell Cardiol., 32, 1401, 2000.10.1006/jmcc.2000.117310900167
Search in Google Scholar
3. Batheja R. et al.: Paradoxical decrease in plasma N-terminal-proBNP (NTproBNP) levels in patients receiving doxorubicin chemotherapy and declining left ventricular ejection fraction. J. Am. Coll. Cardiol., 47, 66A, 2006.
Search in Google Scholar
4. Chen S., Garami M., Gardner D. G.: Doxorubicin Selectively Inhibits Brain Versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes. Hypertension, 34, 1223, 1999.
Search in Google Scholar
5. Dudka J.: The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity. Postepy Hig. Med. Dosw, 60, 241, 2006.
Search in Google Scholar
6. Dudka J. et al.: The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig. Med. Dosw , 63, 225, 2009.
Search in Google Scholar
7. Hacihanefioglu A., Tarkun P., GonulluE.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol., 88, 219, 2008.
Search in Google Scholar
8. Hedhli N., Depre Ch.: Proteasome inhibitors and cardiac cell growth. Cardiovasc. Res., 85, 321, 2010.
Search in Google Scholar
9. Korga A. et al.: The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin. Oxid. Med. Cell Longev., 681367, 2012.10.1155/2012/681367331706122530076
Search in Google Scholar
10. Liu J. et al.: A therapeutic dose of doxorubicin activates ubiquitinproteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am. J. Physiol. Heart Circ. Physiol., 295, H2541, 2008.10.1152/ajpheart.01052.2008265402818978187
Search in Google Scholar
11. Lyu Y. L. et al.: TopoisomeraseIIb-Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxity and Prevention by Dexrazoxane. Cancer Res., 67, 8839, 2007.10.1158/0008-5472.CAN-07-164917875725
Search in Google Scholar
12. Minotti G. et al.: Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxity. Pharmacol. Rev., 56, 185, 2004.10.1124/pr.56.2.615169927
Search in Google Scholar
13. Pichon M. F. et al.: Drug - induced Cardiotoxity Studied by Longitudinal B-Type Natriuretic Peptide Asays and Radionuclide Ventryculography. In Vivo, 19, 567, 2005.
Search in Google Scholar
14. Ranek M. J., Wang X.: Activation of the Ubiquitin Proteasome System in Doxorubicin Cardiomyopathy. Curr. Hypertens. Rep., 11, 389, 2009.
Search in Google Scholar
15. Sayed-Ahmad M. M. et al.: Protection by L-Carnitine Against the Inhibition of Gene Expression of Heart Fatty Acid Binding Protein by Chronic Administration of Doxorubicin. Journal of the Egyptian Nat. Cancer Inst., 4, 275, 2000.
Search in Google Scholar
16. Sayed-Ahmed M. M. et al.: Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur. J. Pharmacol., 640, 143, 2010.10.1016/j.ejphar.2010.05.00220470772
Search in Google Scholar
17. Sun Y. et al.: B-Type Natriuretic Peptide-Induced Cardioprotection against Reperfusion Is Associated with Attenaution of Mitochondrial Permeability Transition. Biol. Pharm. Bull, 32, 1545, 2009.10.1248/bpb.32.154519721230
Search in Google Scholar
18. Szuławska A., Czyż M.: Molecular mechanisms of anthracyclines action. Postepy Hig. Med. Dosw., 60, 78, 2006.
Search in Google Scholar
19. Tsutsui H., Kinugawa S., Matsushima S.: Oxidative Stress and Mitochondrial DNA Damage in Heart Failure”,Circ. J., Suppl Am, A-31, 2008.10.1253/circj.CJ-08-0014
Search in Google Scholar
20. Voortman J., GiacconeG.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer, 6, 129, 2006.
Search in Google Scholar

The influence of proteasome inhibitor on the expression of cardiomyocytes damage markers after incubation with doxorubicin

Abstract

Paradigm

My account